Qingfeng Pharma Group

English

中文

Home

Providing sustainable and high-quality service for human health

Become a leading provider of medical health products and service

Innovating, Efficiency, Striving, Sharing

07/08

2024

Qingfeng Pharmaceutical's Eribulin Mesilate Injection Approved for Marketing in the U.S.

On June 28, the Eribulin Mesilate Injection developed by Qingfeng Pharmaceutical Group was approved for marketing by the U.S. Food and Drug Administration (FDA), making Qingfeng Pharmaceutical the ...

07/06

2024

First in China! Qingfeng Pharmaceutical's Brivaracetam Tablets Approved for Marketing

On June 28, the Brivaracetam tablets (trade name: Qingruitan®) developed by Qingfeng Pharmaceutical Group were officially approved for marketing by the National Medical Products Administration. The...

11/28

2023

The application for the NDA of the new anti-influenza drug GP681 tablets was accepted by NMPA

On November 24, the official website of the Center for Drug Evaluation (CDE) of the NMPA announced that the marketing application for GP681 tablets, a Class 1 innovative chemical drug registered an...